- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05543681
IGC-AD1-Studie zu Agitation bei Demenz aufgrund von Alzheimer (CALMA)
Eine multizentrische, doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase 2 zur Sicherheit und Wirksamkeit von IGC-AD1 bei Agitation bei Teilnehmern mit Demenz aufgrund von Alzheimer
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
CALMA is a multi-center, double-blind, randomized, placebo-controlled clinical trial. The study targets participants aged 60 and older with mild to severe Alzheimer's dementia who have exhibited clinically significant agitation for at least two weeks prior to enrollment. Agitation caused by other conditions or transient symptoms must be ruled out. Eligibility is determined by a baseline Neuropsychiatric Inventory (NPI-12), Agitation subscale score of ≥4 and the International Psychogeriatric Association (IPA) criteria for agitation.
The investigational medication is an oral solution containing two active ingredients: delta-9 tetrahydrocannabinol (THC) and melatonin. The treatment is administered for 42 days, followed by a two-day taper period at the end of the study.
Safety oversight includes daily calls on days 2, 3, and 4, transitioning to calls every third day thereafter. These calls will review study partners logbook entries, changes in concomitant medications, and adverse events.
The primary objective of the study is to evaluate the efficacy of IGC-AD1 on agitation, measured by changes in the Cohen-Mansfield Agitation Inventory (CMAI) scores from baseline to the End of treatment (EOT). The secondary objective is to assess efficacy by examining CMAI score changes from baseline to week two. Additionally, exploratory objectives are outlined in separate documentation.
Blood samples will be collected during the trial for sparse pharmacokinetic (PK) analysis, blood-based CNS biomarker, and genotyping.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
British Columbia
-
Victoria, British Columbia, Kanada, V8R 1J8
- Island Health Authorities
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8M 1W9
- Hamilton Health Sciences , Mcmaster University
-
Toronto, Ontario, Kanada, ON M6A 2E1
- Baycrest Academy for Research and Education , University of Toronto
-
-
Quebec
-
Montreal, Quebec, Kanada, H4H 1R3
- Douglas Hospital Research Center, McGill university
-
-
-
-
-
Bayamón, Puerto Rico, 00961
- SCB Research Center Corp
-
Rio Piedras, Puerto Rico, 00935
- The Alliance, Medical Sciences Campus University of Puerto Rico
-
-
Bayamón
-
Bayamón, Bayamón, Puerto Rico, 00961
- Instituto Sanacoop
-
-
-
-
Florida
-
Maitland, Florida, Vereinigte Staaten, 32751
- ClinCloud, LLC
-
Melbourne, Florida, Vereinigte Staaten, 32940
- ClinCloud, LLC
-
Miami, Florida, Vereinigte Staaten, 33133
- Visionary Investigators Network
-
Miami, Florida, Vereinigte Staaten, 33137
- Miami Jewish Health
-
Miami, Florida, Vereinigte Staaten, 33125
- Central Miami Medical Institute
-
Port Charlotte, Florida, Vereinigte Staaten, 33952
- Neurostudies Inc.
-
Tampa, Florida, Vereinigte Staaten, 33613
- University of South Florida Department of Psychiatry and Behavioral Neurosciences
-
-
Louisiana
-
Metairie, Louisiana, Vereinigte Staaten, 70006
- Tandem Clinical Research GI, LLC
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21237
- MedStar Franklin Square Medical Center Neurology
-
Clinton, Maryland, Vereinigte Staaten, 20735
- Medstar Southern Maryland Hospital Center
-
Olney, Maryland, Vereinigte Staaten, 20832
- Medstar Montgomery Medical Center
-
-
Missouri
-
St Louis, Missouri, Vereinigte Staaten, 63128
- Tekton Research LLC
-
-
New York
-
Amherst, New York, Vereinigte Staaten, 02459
- Dent Neurologic Institute
-
Brooklyn, New York, Vereinigte Staaten, 11229
- Integrative Clinical Trials, LLC
-
Syracuse, New York, Vereinigte Staaten, 13210
- Ichor Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73112
- Lynn Health Science Institute (LHSI)
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02906
- Butler Hospital, Brown University
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78757
- Senior Adults Specialty Research
-
Dallas, Texas, Vereinigte Staaten, 75231
- Kerwin Medical Center
-
Dallas, Texas, Vereinigte Staaten, 75231
- Baylor Scott and White Research Institute
-
-
Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23219
- Dominion Medical Associates, Inc.
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
To be eligible to participate in this study, the participant must meet all the following criteria:
Inclusion Criteria
-
Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures.
-
Must have a Caregiver who is able and willing to comply with all required study procedures.
-
The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others.
-
Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction.
-
Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics.
-
Diagnosis of AD by NIA-AA criteria
-
Clinically significant Agitation assessed by:
- NPI (Agitation) ≥ 4
- The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and
- Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance.
-
Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening.
-
All medications used for behavioral symptoms should be consistent for at least 6 weeks before screening, with allowance for dose changes up to 25%.
-
Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)).
An individual who meets any of the following criteria will be excluded from participation in this study:
Exclusion Criteria
- Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo).
- Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes.
- History of seizures, schizophrenia, or bipolar disorder.
- Has participated in an investigational drug or device study within 30 days prior to study start.
- Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least six weeks before screening.
- History of Alcohol and Drug use disorder, within one year prior to enrollment.
- Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment.
- Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Active Comparator: IGC-AD1Active
IGC-AD1-Active, oral solution with two APIs (THC and melatonin). |
A non-sterile solution for oral administration.
Andere Namen:
|
|
Placebo-Komparator: Placebo Comparator: IGC-AD1 Placebo
IGC-AD1-Placebo, oral solution similar to Active in color, taste, and texture, with excipients but without APIs. |
A non-sterile solution for oral administration similar in color and texture to the Active.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Agitation
Zeitfenster: Baseline to week six
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week six
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Acute Agitation
Zeitfenster: Baseline to week two
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week two
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Agitation at week four
Zeitfenster: Baseline to week four
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week four
|
|
Participant overall wellbeing
Zeitfenster: Baseline to weeks two and six
|
Change in the Clinical Global Impression Scale (CGI) |
Baseline to weeks two and six
|
|
Participant executive functions
Zeitfenster: Baseline to week six
|
Change in Mini-Mental State Examination (MMSE2) score |
Baseline to week six
|
|
Depression
Zeitfenster: Baseline to weeks two, four, and six
|
Change in mean Cornell Scale for Depression in Dementia (CSDD) score |
Baseline to weeks two, four, and six
|
|
Neuropsychiatric symptoms
Zeitfenster: Baseline to weeks two, four, and six
|
Change in mean Neuropsychiatric Inventory (NPI-12) score |
Baseline to weeks two, four, and six
|
|
Participant quality of life
Zeitfenster: Baseline to weeks two, four and six
|
Change in mean Quality of Life in Alzheimer's Disease (QOL-AD) score |
Baseline to weeks two, four and six
|
|
Caregiver burden
Zeitfenster: Baseline to weeks two and six
|
Change in mean Zarit Burden Interview (ZBI) score |
Baseline to weeks two and six
|
|
Psychotropic drugs
Zeitfenster: Baseline to six weeks
|
Change in type and dosage of psychotropic drugs |
Baseline to six weeks
|
|
CYP2C9 polymorphisms on agitation
Zeitfenster: Baseline to weeks two, four and six
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score for each type of metabolizer group (*1/*1, *1/*3, etc.) |
Baseline to weeks two, four and six
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Aberrantes motorisches Verhalten bei Demenz
- Neurologische Manifestationen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Psychische Störungen
- Verhaltenssymptome
- Neurobehaviorale Manifestationen
- Neurokognitive Störungen
- Tauopathien
- Neurodegenerative Krankheiten
- Substanzbezogene Störungen
- Chemisch induzierte Störungen
- Stress, Psychisch
- Dyskinesien
- Psychomotorische Störungen
- Pathologische Zustände, Anzeichen und Symptome
- Verhalten
- Anzeichen und Symptome
- Soziales Verhalten
- Belastung der Pflegekraft
- Angststörungen
- Alzheimer Erkrankung
- Depression
- Marihuana-Missbrauch
- Demenz
- Psychomotorische Agitation
- Aggression
- Motorik
- Bewegung
- Phänomen des Bewegungsapparates muskuloskelettal
- Muskuloskelettaler und neuronales physiologisches Phänomen
- Übung
Andere Studien-ID-Nummern
- IGC-AD1-P2 BIDAG
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .